Pulse Biosciences stock initiated at Outperform by Oppenheimer on nsPFA potential

Published 07/07/2025, 11:50
Pulse Biosciences stock initiated at Outperform by Oppenheimer on nsPFA potential

Investing.com - Oppenheimer initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with an Outperform rating and a $22.00 price target, representing a 12-18 month outlook for the stock. The company, currently valued at $1.03 billion, trades at $15.30, with InvestingPro data showing strong liquidity metrics including a current ratio of 15.58.

The research firm cited Pulse Biosciences’ development of nanosecond pulsed field ablation (nsPFA) technology, a variant of pulsed field ablation that utilizes nanosecond pulse durations and high electric fields ranging from 10 to 80 kilovolts.

According to Oppenheimer, the technology’s hypothesized mechanism of action involves intracellular organelle injury-induced apoptosis, with preliminary evidence suggesting improved safety and efficacy compared to traditional microsecond PFA and radiofrequency ablation (RFA) in applications including thyroid ablation and atrial fibrillation treatments.

While acknowledging that pivotal trials are still needed to validate these benefits, Oppenheimer noted that Pulse Biosciences has "multiple shots on goal" with its technology platform and that "the science makes sense" behind the company’s approach.

The firm also expressed confidence in the company’s leadership, stating that an experienced CEO helps mitigate execution risk, contributing to their constructive outlook on the stock. For deeper insights into PLSE’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.

In other recent news, Pulse Biosciences reported a net loss of $16.8 million for the first quarter of 2025. This financial result reflects increased expenses as the company continues to invest heavily in developing its nanosecond pulse field ablation (NSPFA) technology. Despite the losses, the company raised $14 million through warrant exercises, maintaining a strong cash position of $119.3 million. Pulse Biosciences anticipates generating revenue in the latter half of 2025 as it expands its clinical trials and product offerings. The company is focusing on its NSPFA technology, aiming to disrupt the market for thyroid nodule treatments and atrial fibrillation with less invasive solutions. Analysts from various firms have not yet issued upgrades or downgrades following this report. The company’s strategic focus remains on innovation and expansion, with plans to begin IDE pivotal clinical trials mid-year. Pulse Biosciences is optimistic about its future revenue generation, backed by its ongoing clinical advancements and strategic expansion plans.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.